Open AccessCorrection: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Author(s) -
José Luis Ordóñez,
Ana Teresa Amaral,
Ángel M. Carcaboso,
David HerreroMartín,
María del Carmen García-Macías,
Vicky Sevillano,
Diego AlonsoLópez,
Guillem PascualPasto,
Laura SanSegundo,
Mònica Vilà-Ubach,
Telmo Rodrigues,
Susana Fraile,
Cristina Teodósio,
Agustín MayoIscar,
Miguel Aracil,
Carlos M. Galmarini,
Òscar M. Tirado,
Jaume Mora,
Enrique de Álava
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.18610
Subject(s) - olaparib , trabectedin , medicine , parp inhibitor , oncology , cancer research , sarcoma , poly adp ribose polymerase , soft tissue sarcoma , biology , pathology , polymerase , biochemistry , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom